Jason M Warfel1, James F Papin2, Roman F Wolf2, Lindsey I Zimmerman1, Tod J Merkel1. 1. Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland. 2. Oklahoma Baboon Research Resource, Comparative Medicine, University of Oklahoma Health Sciences Center, Oklahoma City.
Abstract
BACKGROUND: The United States is experiencing a pertussis resurgence that resulted in a 60-year high of 48 000 cases in 2012. The majority of hospitalizations and deaths occur in infants too young to be vaccinated. Neonatal and maternal vaccination have been proposed to protect newborns until the first vaccination, currently recommended at 2 months of age. These interventions result in elevated anti-Bordetella pertussis titers, but there have been no studies demonstrating that these measures confer protection. METHODS: Baboons were vaccinated with acellular pertussis vaccine at 2 days of age or at 2 and 28 days of age. To model maternal vaccination, adult female baboons primed with acellular pertussis vaccine were boosted in the third trimester of pregnancy. Neonatally vaccinated infants, infants born to vaccinated mothers, and naive infants born to unvaccinated mothers were infected with B. pertussis at 5 weeks of age. RESULTS: Naive infant baboons developed severe disease when challenged with B. pertussis at 5 weeks of age. Baboons receiving acellular pertussis vaccine and infants born to mothers vaccinated at the beginning of their third trimester were protected. CONCLUSIONS: Our results demonstrate that neonatal vaccination and maternal vaccination confer protection in the baboon model and support further study of these strategies for protection of newborns from pertussis. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2013. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: The United States is experiencing a pertussis resurgence that resulted in a 60-year high of 48 000 cases in 2012. The majority of hospitalizations and deaths occur in infants too young to be vaccinated. Neonatal and maternal vaccination have been proposed to protect newborns until the first vaccination, currently recommended at 2 months of age. These interventions result in elevated anti-Bordetella pertussis titers, but there have been no studies demonstrating that these measures confer protection. METHODS:Baboons were vaccinated with acellular pertussis vaccine at 2 days of age or at 2 and 28 days of age. To model maternal vaccination, adult female baboons primed with acellular pertussis vaccine were boosted in the third trimester of pregnancy. Neonatally vaccinated infants, infants born to vaccinated mothers, and naive infants born to unvaccinated mothers were infected with B. pertussis at 5 weeks of age. RESULTS: Naive infantbaboons developed severe disease when challenged with B. pertussis at 5 weeks of age. Baboons receiving acellular pertussis vaccine and infants born to mothers vaccinated at the beginning of their third trimester were protected. CONCLUSIONS: Our results demonstrate that neonatal vaccination and maternal vaccination confer protection in the baboon model and support further study of these strategies for protection of newborns from pertussis. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2013. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: B D Meade; A Deforest; K M Edwards; T A Romani; F Lynn; C H O'Brien; C B Swartz; G F Reed; M A Deloria Journal: Pediatrics Date: 1995-09 Impact factor: 7.124
Authors: Frank Kowalzik; Arnaldo Prata Barbosa; Vera Regina Fernandes; Paulo Roberto Carvalho; Maria Luisa Avila-Aguero; Daniel Y T Goh; Anne Goh; Jesus Garcia de Miguel; Fernando Moraga; Joan Roca; Magda Campins; Ming Huang; Jorge Quian; Nicole Riley; Dominique Beck; Thomas Verstraeten Journal: Pediatr Infect Dis J Date: 2007-03 Impact factor: 2.129
Authors: Kristine M Bisgard; F Brian Pascual; Kristen R Ehresmann; Claudia A Miller; Christy Cianfrini; Charles E Jennings; Catherine A Rebmann; Julie Gabel; Stephanie L Schauer; Susan M Lett Journal: Pediatr Infect Dis J Date: 2004-11 Impact factor: 2.129
Authors: Lourdes R A Vaz-de-Lima; Helena Keico Sato; Eder Gatti Fernandes; Ana Paula Sayuri Sato; Lucia C Pawloski; Maria Lucia Tondella; Cyro A de Brito; Expedito J A Luna; Telma Regina M P Carvalhanas; Euclides A de Castilho Journal: Vaccine Date: 2019-05-29 Impact factor: 3.641
Authors: Lindsey I Zimmerman; James F Papin; Jason Warfel; Roman F Wolf; Stanley D Kosanke; Tod J Merkel Journal: Infect Immun Date: 2018-10-25 Impact factor: 3.441
Authors: Parul Kapil; James F Papin; Roman F Wolf; Lindsey I Zimmerman; Leslie D Wagner; Tod J Merkel Journal: J Infect Dis Date: 2018-03-28 Impact factor: 5.226
Authors: Annalee W Nguyen; Ellen K Wagner; Joshua R Laber; Laura L Goodfield; William E Smallridge; Eric T Harvill; James F Papin; Roman F Wolf; Eduardo A Padlan; Andy Bristol; Michael Kaleko; Jennifer A Maynard Journal: Sci Transl Med Date: 2015-12-02 Impact factor: 17.956
Authors: Annalee W Nguyen; Ellen K Wagner; Luciano Posada; Xinlei Liu; Sheila Connelly; James F Papin; Roman F Wolf; Michael Kaleko; Jennifer A Maynard Journal: J Vet Med Sci Date: 2016-09-26 Impact factor: 1.267